ARCHIVES

FDA Proposes New User Fees for Generics and Biosimilar Products

This article is from The Cancer Letter archive.

Vol. 38 No. 03 | January 20, 2012

Download PDF Visit The Full Archive

Related Articles

Lasofoxifene Reduced Breast Cancer Risk In Postmenopausal Osteoporotic Women

November 26, 2010

Once again, Broder Asked What Would He Recommend To Women Aged 40-49

March 18, 1994

FDA Relies on Importation, Fast Approval, and Early Reporting to Combat Drug Shortages

February 24, 2012

In Brief: Gregory Curt Nominated DCT Deputy DCC Seeks Occupational Cancer, Prevention Branch Chiefs

October 26, 1984

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001

Blochs to Sponsor “Fighting Cancer”

May 9, 1986